Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

The United Laboratories International Holdings Limited

ULIHFPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.70
$0.00(0.00%)
U.S. Market is Open • 14:46

The United Laboratories International Holdings Limited Fundamental Analysis

The United Laboratories International Holdings Limited (ULIHF) shows moderate financial fundamentals with a PE ratio of 16.88, profit margin of 15.88%, and ROE of 12.63%. The company generates $8.6B in annual revenue with weak year-over-year growth of 0.14%.

Key Strengths

Cash Position220.67%
PEG Ratio-0.07
Current Ratio1.83

Areas of Concern

No major concerns flagged.
We analyze ULIHF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 51.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
51.2/100

We analyze ULIHF's fundamental strength across five key dimensions:

Efficiency Score

Weak

ULIHF struggles to generate sufficient returns from assets.

ROA > 10%
6.74%

Valuation Score

Excellent

ULIHF trades at attractive valuation levels.

PE < 25
16.88
PEG Ratio < 2
-0.07

Growth Score

Weak

ULIHF faces weak or negative growth trends.

Revenue Growth > 5%
0.14%
EPS Growth > 10%
-2.01%

Financial Health Score

Excellent

ULIHF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.29
Current Ratio > 1
1.83

Profitability Score

Moderate

ULIHF maintains healthy but balanced margins.

ROE > 15%
12.63%
Net Margin ≥ 15%
15.88%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ULIHF Expensive or Cheap?

P/E Ratio

ULIHF trades at 16.88 times earnings. This indicates a fair valuation.

16.88

PEG Ratio

When adjusting for growth, ULIHF's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values The United Laboratories International Holdings Limited at 2.02 times its book value. This may indicate undervaluation.

2.02

EV/EBITDA

Enterprise value stands at 10.30 times EBITDA. This signals the market has high growth expectations.

10.30

How Well Does ULIHF Make Money?

Net Profit Margin

For every $100 in sales, The United Laboratories International Holdings Limited keeps $15.88 as profit after all expenses.

15.88%

Operating Margin

Core operations generate 17.31 in profit for every $100 in revenue, before interest and taxes.

17.31%

ROE

Management delivers $12.63 in profit for every $100 of shareholder equity.

12.63%

ROA

The United Laboratories International Holdings Limited generates $6.74 in profit for every $100 in assets, demonstrating efficient asset deployment.

6.74%

Following the Money - Real Cash Generation

Operating Cash Flow

The United Laboratories International Holdings Limited produces operating cash flow of $891.40M, showing steady but balanced cash generation.

$891.40M

Free Cash Flow

The United Laboratories International Holdings Limited produces free cash flow of $275.05M, offering steady but limited capital for shareholder returns and expansion.

$275.05M

FCF Per Share

Each share generates $0.14 in free cash annually.

$0.14

FCF Yield

ULIHF converts 1.80% of its market value into free cash.

1.80%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

16.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.02

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.76

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.29

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.83

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.13

vs 25 benchmark

ROA

Return on assets percentage

0.07

vs 25 benchmark

ROCE

Return on capital employed

0.11

vs 25 benchmark

How ULIHF Stacks Against Its Sector Peers

MetricULIHF ValueSector AveragePerformance
P/E Ratio16.8828.50 Better (Cheaper)
ROE12.63%836.00% Weak
Net Margin15.88%-22564.00% (disorted) Strong
Debt/Equity0.290.30 Neutral
Current Ratio1.834.53 Neutral
ROA6.74%-14951.00% (disorted) Weak

ULIHF outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews The United Laboratories International Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

47.96%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

274.04%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

60.31%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ